Prostate cancer screening in men ages 75 and older fell by 8 percentage points aftertask force recommendation

Health Affairs

Volumn 32, Issue 3, 2013, Pages 596-602

  Howard, David H ^a   Tangka, Florence K ^b   Guy, Gery P ^b   Ekwueme, Donatus U ^b   Lipscomb, Joseph ^c  

^a EMORY UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER SCREENING; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSTATE CANCER; SELF REPORT; SENSITIVITY ANALYSIS; SOCIAL STATUS;

AGE FACTORS; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MEDICARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNNECESSARY PROCEDURES; UTILIZATION REVIEW;

EID: 84875034103     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0555     Document Type: Article

References (25)

1. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102(9):605-13.
2. US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force rec-ommendation statement. Ann Intern Med. 2008;149(3):185-91.
3. US Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann Intern Med. 2002;137(11):915.
4. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011;103(6):520-3.
5. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommenda-tions and prostate cancer screening rates. JAMA. 2012;307(16):1692-4.
6. Hall HI, Van Den Eeden SK, Tolsma DD, Rardin K, Thompson T, Hughes Sinclair A, et al. Testing for prostate and colorectal cancer: comparison of self-report and medical record audit. Prev Med. 2004;39(1):27-35.
7. Chan EC, Vernon SW, Ahn C, Greisinger A. Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites. Am J Public Health. 2004;94(8):1336-8.
8. Guerra CE, Jacobs SE, Holmes JH, Shea JA. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. J Gen Intern Med. 2007; 22(7):901-7.
9. Linder SK, Hawley ST, Cooper CP, Scholl LE, Jibaja-Weiss M, Volk RJ. Primary care physicians' reported use of pre-screening discussions for prostate cancer screening: a cross-work was supported by an Interagency Personnel Agreement with the Centers for Disease Control and Prevention. The findings and conclusions in this report sectional survey. BMC Family Pract. 2009;10:19.
10. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
11. To access the Appendix, click on the Appendix link in the box to the right of the article online
12. Howard DH. Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med. 2012;172(16):1267-8.
13. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13): 1310-9.
14. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13): 1320-8.
15. Barry MJ. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med. 2009;360(13): 1351-4.
16. Han PK, Klabunde CN, Breen N, Yuan G, Grauman A, Davis WW, et al. Multiple clinical practice guidelines for breast and cervical cancer screening: perceptions of US primary care physicians. Med Care. 2011;49(2):139-48.
17. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98.
18. American Urological Association. Prostate-specific antigen best practice statement: 2009 update [Internet]. Linthicum (MD): AUA; are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. 2009 [cited 2013 Feb 20]. Available from: http://www.auanet.org/ content/guidelines-and-qualitycare/clinical-guidelines/mainreports/psa09.pdf
19. Kerfoot BP, Holmberg EF, Lawler EV, Krupat E, Conlin PR. Practitioner-level determinants of inappropriate prostate-specific antigen screening. Arch Intern Med. 2007;167(13):1367-72.
20. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296(19): 2336-42.
21. Sima CS, Panageas KS, Schrag D. Cancer screening among patients with advanced cancer. JAMA. 2010;304(14):1584-91.
22. Hoffman RM, Couper MP, Zikmund Fisher BJ, Levin CA, McNaughton-collins M, Helitzer DL, et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med. 2009; 169(17):1611-8.
23. Guerra CE, Gimotty PA, Shea JA, Pagán JA, Schwartz JS, Armstrong K. Effect of guidelines on primary care physician use of PSA screening: results from the Community Tracking Study Physician Survey. Med Decis Making. 2008;28(5): 681-9.
24. Lewis CL, Couper MP, Levin CA, Pignone MP, Zikmund Fisher BJ. Plans to stop cancer screening tests among adults who recently considered screening. J Gen Intern Med. 2010;25(8):859-64.
25. Howard DH, Huang Y. Serious health events and discontinuation of routine cancer screening. Med Decis Making. 2012;32(4):627-35.